Over the past 12 months, 0 insiders at Catalent, Inc. filed 0 open-market SEC Form 4 transactions on CTLT: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 11, 24 | Michelle R RyanDirector | SELL | 2.8K | $59.70 | $167K |
| Oct 18, 24 | Joseph Anthony FerraroSVP, General Counsel, CCO | SELL | 320 | $59.97 | $19K |
| Sep 26, 24 | David McErlaneGroup President, Biologics | SELL | 2.0K | $59.97 | $120K |
| Aug 2, 24 | Lisa EvoliSVP, Chief HR Officer | SELL | 3.9K | $59.67 | $230K |
| Aug 2, 24 | Joseph Anthony FerraroSVP, General Counsel, CCO | SELL | 608 | $59.58 | $36K |
| Aug 2, 24 | Aristippos GennadiosGroup Pres. Pharma & Consumer | SELL | 1.2K | $59.55 | $70K |
| Aug 2, 24 | Scott GuntherSVP, Quality & Reg. Affairs | SELL | 666 | $59.55 | $40K |
| Aug 2, 24 | Ricky HopsonPres. BioProduct Delivery, CoS | SELL | 662 | $59.56 | $39K |
| Jul 29, 24 | Aristippos GennadiosGroup Pres. Pharma & Consumer | SELL | 349 | $58.70 | $20K |
| Jul 29, 24 | Scott GuntherSVP, Quality & Reg. Affairs | SELL | 283 | $58.69 | $17K |
| Jul 29, 24 | Ricky HopsonPres. BioProduct Delivery, CoS | SELL | 206 | $58.67 | $12K |
| Jul 29, 24 | Alessandro MaselliPresident & CEO | SELL | 9.1K | $58.76 | $534K |
| Jul 8, 24 | Matti MasanovichSVP, Chief Financial Officer | SELL | 3.0K | $56.74 | $170K |
| Jun 4, 24 | Ricky HopsonPres. BioProduct Delivery, CoS | SELL | 1.4K | $54.26 | $76K |
| Mar 15, 24 | Scott GuntherSVP, Quality & Reg. Affairs | SELL | 387 | $56.20 | $22K |
| Aug 31, 23 | Michelle R RyanDirector | BUY | 1.0K | $49.98 | $50K |
| Aug 30, 23 | John J GreischExecutive Chair | BUY | 21.0K | $50.24 | $1.1M |
| Aug 24, 23 | Jonathan ArnoldSVP, CCO & Div. Head BioP Del. | SELL | 87 | $44.87 | $4K |
| Aug 24, 23 | Lorenzo CarlettiSVP Global Ops Ph & Cons Hlth | SELL | 216 | $44.71 | $10K |
| Aug 24, 23 | Steven L FasmanEVP & Chief Admin Officer | SELL | 817 | $44.65 | $36K |
| Aug 24, 23 | Aristippos GennadiosGroup Pres. Pharma & Consumer | SELL | 396 | $44.49 | $18K |
| Aug 24, 23 | Michael J GrippoSVP, Strategy & Corp. Dev. | SELL | 390 | $44.50 | $17K |
| Aug 24, 23 | Scott GuntherSVP, Quality & Reg. Affairs | SELL | 269 | $44.57 | $12K |
| Aug 24, 23 | Thomas W HawkeswoodPres. Pharma Prod Delivery Div | SELL | 147 | $44.72 | $7K |
| Aug 24, 23 | Ricky HopsonPres. Clinical Dev Supply Div | SELL | 276 | $44.56 | $12K |
| Aug 24, 23 | Patricia HuntPres. Consumer Health Div | SELL | 106 | $44.77 | $5K |
| Aug 24, 23 | Charles LickfoldSVP, CIO | SELL | 190 | $44.72 | $8K |
| Aug 24, 23 | Alessandro MaselliPresident & CEO | SELL | 2.0K | $45.15 | $88K |
| Aug 24, 23 | Ricardo PravdaChief Transformation Officer | SELL | 379 | $44.47 | $17K |
| Aug 1, 23 | Jonathan ArnoldSVP, CCO & Div. Head BioP Del. | SELL | 62 | $47.80 | $3K |
| Aug 1, 23 | Lorenzo CarlettiSVP Global Ops Ph & Cons Hlth | SELL | 383 | $47.77 | $18K |
| Aug 1, 23 | Steven L FasmanEVP & Chief Admin Officer | SELL | 1.1K | $47.76 | $52K |
| Aug 1, 23 | Aristippos GennadiosGroup Pres. Pharma & Consumer | SELL | 220 | $47.87 | $11K |
| Aug 1, 23 | Michael J GrippoSVP, Strategy & Corp. Dev. | SELL | 241 | $47.88 | $12K |
| Aug 1, 23 | Scott GuntherSVP, Quality & Reg. Affairs | SELL | 190 | $47.90 | $9K |
| Aug 1, 23 | Thomas W HawkeswoodPres. Pharma Prod Delivery Div | SELL | 258 | $47.97 | $12K |
| Aug 1, 23 | Ricky HopsonPres. Clinical Dev Supply Div | SELL | 195 | $47.86 | $9K |
| Aug 1, 23 | Patricia HuntPres. Consumer Health Div | SELL | 161 | $47.95 | $8K |
| Aug 1, 23 | Charles LickfoldSVP, CIO | SELL | 135 | $47.90 | $6K |
| Aug 1, 23 | Alessandro MaselliPresident & CEO | SELL | 879 | $47.75 | $41K |
| Aug 1, 23 | Ricardo PravdaChief Transformation Officer | SELL | 222 | $47.78 | $11K |
| May 1, 23 | Manja BoermanPres. BioModalities Division | SELL | 1.4K | $49.86 | $72K |
| May 1, 23 | Mario GargiuloSVP, Ops, Biologics Europe | SELL | 678 | $49.86 | $34K |
| Jan 23, 23 | Ricky HopsonPres. Clinical Dev Supply Div | SELL | 643 | $49.36 | $32K |
| Dec 5, 22 | Manja BoermanPres. BioModalities Division | SELL | 780 | $51.70 | $40K |
| Oct 31, 22 | Michael J GrippoSVP, Strategy & Corp. Dev. | SELL | 2.5K | $65.83 | $161K |
| Oct 10, 22 | Thomas W HawkeswoodPres. Pharma Prod Delivery Div | SELL | 930 | $77.46 | $72K |
| Aug 31, 22 | Ricky HopsonPres. Clinical Dev Supply Div | SELL | 2.2K | $89.59 | $199K |
| Aug 26, 22 | Scott GuntherSVP, Quality & Reg. Affairs | SELL | 1.6K | $104.07 | $171K |
| Aug 26, 22 | Michael A. RileyPres. Bio Product Delivery Div | SELL | 2.5K | $104.07 | $259K |
Over the past 12 months, insiders at Catalent, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on CTLT, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market CTLT insider purchase in our data was $1.1M by John J Greisch, Executive Chair, filed on Aug 30, 23.
0 different insiders at Catalent, Inc. filed open-market SEC Form 4 transactions on CTLT over the last 12 months.
InsiderTape plots every CTLT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Catalent, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →